BR112019012709A2 - composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica. - Google Patents

composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica. Download PDF

Info

Publication number
BR112019012709A2
BR112019012709A2 BR112019012709A BR112019012709A BR112019012709A2 BR 112019012709 A2 BR112019012709 A2 BR 112019012709A2 BR 112019012709 A BR112019012709 A BR 112019012709A BR 112019012709 A BR112019012709 A BR 112019012709A BR 112019012709 A2 BR112019012709 A2 BR 112019012709A2
Authority
BR
Brazil
Prior art keywords
compound
disease
pharmaceutically acceptable
fact
methyl
Prior art date
Application number
BR112019012709A
Other languages
English (en)
Portuguese (pt)
Inventor
Nordvall Gunnar
Sandin Johan
Forsell Pontus
Original Assignee
AlzeCure Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AlzeCure Pharma AB filed Critical AlzeCure Pharma AB
Publication of BR112019012709A2 publication Critical patent/BR112019012709A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019012709A 2016-12-21 2017-12-21 composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica. BR112019012709A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1651706 2016-12-21
PCT/GB2017/053868 WO2018115891A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
BR112019012709A2 true BR112019012709A2 (pt) 2019-11-26

Family

ID=60923799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012709A BR112019012709A2 (pt) 2016-12-21 2017-12-21 composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica.

Country Status (12)

Country Link
US (1) US20200113910A1 (cg-RX-API-DMAC7.html)
EP (1) EP3558320A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020502225A (cg-RX-API-DMAC7.html)
KR (1) KR20190098982A (cg-RX-API-DMAC7.html)
CN (1) CN110167558A (cg-RX-API-DMAC7.html)
AU (1) AU2017380583A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019012709A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046289A1 (cg-RX-API-DMAC7.html)
IL (1) IL267086A (cg-RX-API-DMAC7.html)
MX (1) MX2019007606A (cg-RX-API-DMAC7.html)
RU (1) RU2019120431A (cg-RX-API-DMAC7.html)
WO (1) WO2018115891A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) * 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
CA2765030C (en) * 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2011070177A2 (en) * 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators

Also Published As

Publication number Publication date
MX2019007606A (es) 2020-07-29
WO2018115891A1 (en) 2018-06-28
RU2019120431A (ru) 2021-01-22
IL267086A (en) 2019-08-29
RU2019120431A3 (cg-RX-API-DMAC7.html) 2021-03-09
AU2017380583A1 (en) 2019-06-27
US20200113910A1 (en) 2020-04-16
CA3046289A1 (en) 2018-06-28
CN110167558A (zh) 2019-08-23
JP2020502225A (ja) 2020-01-23
EP3558320A1 (en) 2019-10-30
KR20190098982A (ko) 2019-08-23

Similar Documents

Publication Publication Date Title
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
BR112013003097B1 (pt) 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
TWI743484B (zh) 用於治療、改善或預防與tau聚集物相關之病症的新穎化合物
TWI688565B (zh) 萘啶二酮(naphthyridinedione)衍生物
US20200113910A1 (en) Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
WO2011084642A1 (en) Compound suitable for the treatment of synucleopathies
BR112019014235A2 (pt) Inibidores bicíclicos de histona desacetilase
TW200904436A (en) Arylamide pyrimidone derivatives
BRPI0718510A2 (pt) Derivados de 3-amino piridina para o tratamento de desordens metabólicas
BR112020026619A2 (pt) Composto, método para tratar e/ou prevenir uma doença que apresenta sinalização prejudicada de neurotrofinas e/ou outros fatores trópicos, uso de um composto, produto de combinação, kit de partes, e, processo para a preparação de um composto
CA3147623A1 (en) Triazine derivatives for treating diseases relating to neurotrophins
JP6831376B2 (ja) トリアゾール誘導体
US20210261513A1 (en) 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
WO2024222837A1 (zh) 四氢萘基丙基氨甲基哌啶芳基(磺)酰胺衍生物、其制备方法和应用
BR122025016812A2 (pt) Compostos de adeninas, uso dos mesmos, composição farmacêutica, método para modular a atividade da quinase pink1 em um indivíduo, e kit
KR101459720B1 (ko) 세로토닌 5-HT6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1H-피라졸로[3,4-c]피리딘-7(4H)-온 화합물
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
EA052182B1 (ru) Гетеробиарильные соединения и визуализирующие агенты для визуализации белка хантингтина

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements